<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856713</url>
  </required_header>
  <id_info>
    <org_study_id>NRL972-01/2005 (ACPS)</org_study_id>
    <nct_id>NCT00856713</nct_id>
  </id_info>
  <brief_title>Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers</brief_title>
  <official_title>A Study in Healthy Volunteers and Patients With Liver Cirrhosis to Assess the Effects of Age, Gender, and Stable Liver Disease on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) as an in-Vivo Marker of Liver Function in Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in healthy volunteers and patients with liver cirrhosis to assess the effects of age,
      gender, and stable liver disease on the clearance of cholyl-lysyl-fluorescein (NRL972)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of NRL972 in healthy subjects and patients with hepatic cirrhosis</measure>
    <time_frame>Up to 4 hrs post administration of NRL972</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events and changes in physical findings from baseline</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on vital signs: blood pressure, pulse rate</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on electrocardiogram</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in haematology, clinical chemistry, urinalysis</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1 YM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 EM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 YF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 EF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 CTP-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hepatic cirrhosis CTP-class A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 CTP-BC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hepatic cirrhosis CTP-class B and C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single intravenous dose of 2 mg NRL972</description>
    <arm_group_label>1 YM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single intravenous dose of 2 mg NRL972</description>
    <arm_group_label>2 EM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single intravenous dose of 2 mg NRL972</description>
    <arm_group_label>3 YF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single intravenous dose of 2 mg NRL972</description>
    <arm_group_label>4 EF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single intravenous dose of 2 mg NRL972</description>
    <arm_group_label>5 CTP-A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single intravenous dose of 2 mg NRL972</description>
    <arm_group_label>6 CTP-BC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects meeting the following conditions will be eligible for enrolment:

        General - all subjects

          1. Males or females (females of non-child-bearing potential or of child-bearing potential
             while taking medically appropriate contraception)

          2. Caucasian

          3. BMI: between 19 and 34 kg.m-2

          4. BW: between 45 and 110 kg

          5. willing and able to provide informed consent

             Healthy volunteers (group N)

          6. Age: 18 - 40 years (inclusive) and &gt; 60 years

          7. Assessed as healthy based on the pre-study examination

             Hepatic cirrhosis

          8. Age: 18 - 75 years

          9. stable compensated liver cirrhosis (cryptogenic, posthepatic, alcoholic) with
             histo-logical or macroscopic (e.g. laparascopy, biopsy, ultrasound sonography or other
             adequate imaging techniques) confirmation

        Exclusion Criteria:

        Subjects of any of the following categories will be excluded from enrolment:

        General - all subjects

          1. Previous participation in the trial

          2. Participant in any other trial during the last 90 days

          3. Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL
             within the last 3 months

          4. History of any clinically relevant allergy

          5. Presence of acute or chronic infection

          6. Uncontrolled diabetes mellitus

          7. Resting systolic blood pressure &gt; 160 or &lt; 90 mmHg, diastolic blood pressure &gt; 95 or &lt;
             50 mmHg

          8. Clinically relevant ECG-abnormalities, prolonged QTc with &gt; 450 msec in males and &gt;
             460 msec in females in particular

          9. Positive HIV test

         10. Positive alcohol or urine drug test on recruitment

         11. Daily use of &gt; 30 gr alcohol

         12. Smoking more than 15 cigarettes/day or equivalent of other tobacco products

         13. Use of prohibited medication

         14. Suspicion or evidence that the subject is not trustworthy and reliable

         15. Suspicion or evidence that the subject is not able to make a free consent or to
             under-stand the information in this regard

             General - all females

         16. Positive pregnancy test

         17. Lactating

         18. Not using appropriate contraception in premenopausal women

             All healthy subjects

         19. Presence or history of any relevant comorbidity

         20. Presence of any relevant abnormality in the laboratory safety tests, especially low
             Hemoglobin, increased liver enzymes, reduced serum creatinine

         21. Positive serology for HBsAg, anti HBc and anti HCV

         22. History of alcohol and/or drug abuse

             Patients with hepatic disease

         23. Biliary liver cirrhosis

         24. Liver impairment due to space-occupying processes (e.g. carcinoma)

         25. State after liver transplantation or patient scheduled for liver transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-JÃ¼rgen Gruss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zahariy Krastev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Ivan Rilski's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMHAPT St Ivan Rilski's University Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>March 5, 2009</last_update_submitted>
  <last_update_submitted_qc>March 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President Clinical Development</name_title>
    <organization>Norgine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

